A plethora of other IL2-based agents and therapies may still have the potential to benefit cancer patients.538 As a natural “non-α IL-2 variant”, IL-15 mainly combines with the IL-15Rα subunit forming IL-15-IL-15Rα dimers on APCs and signals through IL-2/15Rβ (CD122)/cγ (CD132) on T cells or NK cells, with no binding to CD25539 (Table 3 and Supplementary Table 6). This evidence concerns the gene IL2 and cancer.